Safety and Efficacy of SofWave Treatment to Lift the Upper Lip and Improve the Peri-Oral Rhytids

Last updated: May 12, 2025
Sponsor: Sofwave Medical LTD
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Sofwave

Clinical Study ID

NCT06104514
Sofwave20
  • Ages 35-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Open-label, non-randomized, prospective, multi-center, self-controlled

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Healthy female and male subjects between the ages 35-80.

  2. Desire to improve the peri-oral appearance, decrease the distance between the noseand the upper lip (Philtral column length) and/or reduce the peri-oral rhytids.

  3. Philtral column height>15mm or/and has moderate severe perioral rhytids.

  4. Subject agrees to maintain a stable weight (i.e., within 5% of total body weight) bynot making any major changes in their diet or exercise routine during the study.

  5. Able and willing to comply with all visits, treatments and evaluation schedules andrequirements.

  6. Able to understand and provide written Informed Consent.

  7. Willing to have photographs of the treated areas. Agree for de-identified studyimages to be used in evaluations, publications and presentations.

  8. Agree not to undergo any other facial treatments for a period of 3 months followingSofWave treatments.

  9. Women of child-bearing age are required to be using a reliable method of birthcontrol at least 3 months prior to study enrollment.

Exclusion

Exclusion Criteria:

  1. Pregnant or planning to become pregnant, having given birth less than 3 months ago,and/or breast feeding.

  2. Current smoker or has history of heavy smoking (25 cigarettes per day or more) inpast 10 years.

  3. Melanoma active malignancy or history of malignancy in the past 5 years.

  4. Any other non-melanoma malignancy active malignancy or history of malignancy in thepast 5 years within the intended to treat area.

  5. Previous chemotherapy treatments.

  6. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. anydisease state that in the opinion of the investigator may interfere with theanesthesia, treatment, or healing process).

  7. History of chronic drug or alcohol abuse

  8. History of Epileptic seizures.

  9. History of immunosuppression/immune deficiency disorders (including HIV infection orAIDS) or currently using immunosuppressive medications.

  10. Suffering from hormonal imbalance, whether related to thyroid, pituitary, orandrogen.

  11. History of significant lymphatic drainage problems within the facial areas.

  12. History of epidermal or dermal disorders (particularly involving collagen ormicrovascularity), including collagen vascular disease or vasculitic disorders.

  13. Excessive subcutaneous fat on the face.

  14. Taking Isotretinoin or other oral retinoid within the past 6 months; takinganti-coagulant within the past 2 weeks

  15. Currently taking or has taken diet pills or weight control supplements within thepast month.

  16. Non-stable weight ( ±5%) within the past month.

  17. Medical disorder that may hinder the wound healing or immune response (such as blooddisorder, inflammatory disease, etc.)

  18. Known allergy to Lidocaine, Tetracaine, Xylocaine, Epinephrine or antibiotics.

  19. Skin disorders (skin systematic or local infections or rashes, extensive scarring,psoriasis, etc.) in the treatment area.

  20. Severe solar elastosis at the intended to treat area.

  21. Tattoo or former tattoo at or near treatment area.

  22. Tendency for Melasma inflammation.

  23. Significant scarring, atrophic scars in the area to be treated, or has a history ofatrophic scars or keloids or prone to bruising.

  24. Surgical or traumatic scar in the intended to treat area.

  25. Presence of a metal stent or implant in the facial area (e.g. braces; dentalimplants are not excluded).

  26. History of cosmetic treatments in the facial area to be treated, includingblepharoplasty, direct specific forehead lift and facial skin-tightening procedurewithin the 6 months;injectable (Botox or fillers) of any type within the 12 months;ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatmentwithin the past 6 months, dermabrasion or deep facial peels within the past 12months; facelift or neck lift within the past 12 months.

  27. Currently enrolled in a clinical study of any other unapproved investigational drugor device.

  28. As per the investigator's discretion, any physical or mental condition which mightmake it unsafe for the subject to participate in this study.

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Sofwave
Phase:
Study Start date:
July 01, 2023
Estimated Completion Date:
May 12, 2025

Study Description

Patients will receive 2 monthly treatments with the SofWave system and will be followed up twice: at 4 weeks and 12 weeks after last treatment (FU1-FU2).

Connect with a study center

  • Premier Plastic Surgery

    Palo Alto, California 94306
    United States

    Site Not Available

  • Cosmetic Laser Dermatology

    San Diego, California 92121
    United States

    Site Not Available

  • Advanced dermatoloy

    Lincolnshire, Illinois 60069
    United States

    Site Not Available

  • Aesthetic Revolution Las Vegas

    Las Vegas, Nevada 89148
    United States

    Site Not Available

  • New Jersey Plastic Surgeon

    Montclair, New Jersey 07042
    United States

    Site Not Available

  • UnionDerm

    New York, New York 10003
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.